BUZZ - Stryker shares fall as long-time CEO Lobo steps down, with COO Styles set to succeed
路透社2026/10/06 12:56October 6th - Stryker (SYK.N) shares fell more than 3% in pre-market trading to $275.44. Current President and Chief Operating Officer Spencer Stiles will succeed Kevin Lobo as the CEO of the medical device manufacturer. Lobo, who has served as CEO since 2012, will become Executive Chairman starting January 1. Lobo oversaw more than 60 acquisitions, including the purchase of robotic surgery company Mako, which helped transform the orthopedic sector. Out of 29 brokerage firms, 24 rate the stock as "buy" or higher, while 5 recommend "hold"; the median target price is $380, according to data compiled by LSEG. As of the previous trading day's close, the stock was down 18.85% year-to-date. (For the convenience of non-English speakers, Reuters has automated the translation of its report into several other languages. As automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters assumes no responsibility for any damages or losses arising from the use of automated translation features.)
October 6 - ** Stryker (SYK.N) shares fell more than 3% in pre-market trading to $275.44
** Current President and Chief Operating Officer Spencer Stiles will succeed Kevin Lobo as CEO of the medical device manufacturer
** Kevin Lobo, who has served as CEO since 2012, will become Executive Chairman effective January 1
** Lobo led more than 60 acquisitions, including that of robotics surgery company Mako, which drove transformation in the orthopedics field
** Out of 29 brokerages, 24 rate the stock as "buy" or higher, and 5 recommend "hold"; the median price target is $380 — data compiled by LSEG
** As of the close of the previous trading day, the stock had fallen 18.85% year to date
(To assist non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or may lack necessary context, Reuters does not guarantee the accuracy of these automated translations and provides them for reader convenience only. Reuters accepts no responsibility for any damage or loss arising from use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
